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The receptor for advanced glycation end products (RAGE)
is a multiligand receptor that has been shown to con-
tribute to the pathogenesis of diabetes, atherosclerosis,
and neurodegeneration. However, its role in asthma
and allergic airway disease is largely unknown. These
studies use a house dust mite (HDM) mouse model of
asthma/allergic airway disease. Respiratory mechanics
were assessed and compared between wild-type and
RAGE knockout mice. Bronchovascular architecture
was assessed with quantitative scoring, and expression
of RAGE, immunoglobulins, and relevant cytokines was
assessed by standard protein detection methods and/or
quantitative RT-PCR. The absence of RAGE abolishes
most assessed measures of pathology, including airway
hypersensitivity (resistance, tissue damping, and elas-
tance), eosinophilic inflammation, and airway remod-
eling. IL-4 secretion, isotype class switching, and anti-
gen recognition are intact in the absence of RAGE. In
contrast, normal increases in IL-5, IL-13, eotaxin, and
eotaxin-2 production are abrogated in the RAGE knock-
outs. IL-17 indicates complex regulation, with elevated
baseline expression in RAGE knockouts, but no induc-
tion in response to allergen. Treatment of WTmice with
an inhibitor of RAGEmarkedly reduces inflammation in
the HDM model, suggesting that RAGE inhibition may
serve as a promising therapeutic strategy. Finally, the
results in theHDMmodel are recapitulated in an ovalbu-
minmodel of asthma, suggesting that RAGE plays a role
in asthma irrespective of the identity of the allergens
involved. (Am J Pathol 2012, 181:1215–1225; http://dx.doi.
org/10.1016/j.ajpath.2012.06.031)
The receptor for advanced glycation end products
(RAGE) is a multiligand receptor first identified as a po-tential mediator in diabetes.1 RAGE has many additional
ligands, including S100 proteins, HMGB1, amyloid , and
heparin.2,3 The current paradigm maintains that membrane
RAGE (mRAGE) signaling is proinflammatory, whereas sol-
uble RAGE (sRAGE), a secreted form of RAGE, is generally
anti-inflammatory because it scavenges proinflammatory li-
gands.4 RAGE transcript and protein are predominantly
expressed in the lung,5 and specifically by pulmonary type
I alveolar epithelial cells,6 suggesting that RAGE has an
important role in lung pathophysiology.
Recent studies suggest that RAGE contributes to pul-
monary disease; RAGE knockout mice are protected
against hyperoxia-induced lung injury7 and exhibit atten-
uated responses to bacterial pneumonia.8 RAGE also
appears to have an important role in pulmonary fibrosis,
but this depends on the type of injury model used to
generate the fibrotic response.6,9–11 RAGE expression is
altered in these models of disease, for example, the ap-
pearance of sRAGE in the bronchoalveolar lavage fluid
(BALF) in a mouse model of pneumonia and loss of RAGE
expression in models of pulmonary fibrosis.
Asthma/allergic airway disease (AAD) is a main inflam-
matory condition of modern industrial societies, seen with
increasing frequency throughout the developing world.
Bronchodilators and corticosteroids remain the main-
stays of therapy, but they are ineffective or inadequate for
some groups of patients. Novel therapies that exploit
auxiliary mechanisms of disease and that incur fewer
side effects than chronic corticosteroid treatment are
greatly needed. To date, there appears to have been no
studies of RAGE in animal models of asthma. A few
studies in humans have suggested that there is an in-
crease in the levels of RAGE ligands HMGB112 and
S100A8/A913 in samples from patients with asthma com-
pared with controls, suggesting that RAGE may contrib-
ute to asthma/AAD pathogenesis. Although one recent
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AJP October 2012, Vol. 181, No. 4study suggested that sRAGE is increased concomitantly
with HMGB1 in patients with asthma,12 another sug-
gested a decrease in sRAGE and no change in HMGB1
in patients with neutrophilic asthma.14 Apart from the
potential inconsistency between the latter two results,
those studies have not provided mechanistic insight as to
the role of mRAGE versus sRAGE in asthma, nor have
they elucidated how cytokines and chemokines key to
allergic disease are differentially regulated in the pres-
ence or absence of RAGE.
The present study used a house dust mite (HDM) an-
tigen sensitization/challenge model of asthma/AAD to di-
rectly assess the role of RAGE in asthma/AAD. An ad-
vantage of this model is that sensitization and challenge
are effected by intranasal HDM extract application in the
absence of adjuvant. Moreover, HDM antigen has been
identified as a key contributor to asthma pathogenesis in
humans and is a known trigger of acute asthmatic exac-
erbations.15,16 To strengthen the applicability of the results
and to further clarify mechanism, analogous experiments
were also performed in an ovalbumin model of AAD to
ensure that any effects of RAGE are not specific to the
model investigated. Wild-type (WT) C57BL/6 strain mice
subjected to these models develop airway hyperrespon-
siveness to methacholine challenge; bronchial, vascular,
and interstitial eosinophilia; goblet cell hyperplasia with mu-
cus hypersecretion; and elevated titers of IgE, the immuno-
globulin classmost closely associated with allergic disease.
Materials and Methods
Animals and Reagents
WT male C57BL/6 mice were purchased from Taconic
(Hudson, NY). Founder RAGE knockout (RAGE KO) mice
were provided by Dr. A. Bierhaus (University of Heidel-
berg), and from these mice a breeding colony was initi-
ated.6,11,17 These mice are congenic with the C57BL/6
background. RAGE KO mice were age- and sex-
matched to WT mice for each experiment. In all cases
mice were housed in the animal care facility of the Uni-
versity of Pittsburgh, and experimental protocols were
approved by the University’s Institutional Animal Care
and Use Committee. HDM extract was obtained from
Greer Laboratories (Lenoir, NC). Mouse serum albumin
(MSA) was purchased from Sigma (St. Louis, MO).
sRAGE was purified frommouse lung tissue, and endotoxin
was removed with a Detoxi-Gel column (Thermo-Fisher) as
described previously.2,18 Purity was confirmed by SDS-
PAGE and Coomassie Brilliant Blue staining. Specific bind-
ing of the purified sRAGE to a known RAGE ligand, HMGB1,
was assessed as described elsewhere19 to ensure ligand
binding was intact in the purified protein.
Models of Allergic Airway Inflammation/Asthma
AAD/asthma was induced in mice with the use of one of
three protocols. In the first protocol, 8-week-old male WT
or RAGE KO mice were treated intranasally (i.n.) four
times per week for 7 weeks with 40 g of HDM extract in
25 L of saline. Control mice were treated with salinevehicle alone. Mice were sacrificed 48 hours after the last
treatment. In the second protocol, 8-week-old male WT
C57BL/6 mice were treated i.n. five times per week for 3
weeks with one of the following six treatments [in each
case in 25 L of phosphate-buffered saline (PBS)]: saline
control, 25 g of MSA alone, 25 g of mouse sRAGE
alone, 40 g of HDM extract alone, 40 g of HDM extract
with 25 g of MSA, or 40 g of HDM extract with 25 g of
sRAGE. The third protocol used ovalbumin as the sensi-
tization/challenge antigen. Sensitization was effected by
intraperitoneal treatment with 50 g of ovalbumin (Sigma)
with 2 mg of aluminum hydroxide gel (Brenntag, Reading,
PA) in 0.5 mL of saline on days 0 and 7. Control mice
were given alum with saline alone. Intranasal challenge
commenced at day 14 with 10 g of ovalbumin in 25 L
of saline (or saline alone, in controls), continuing on al-
ternate days for a total of three treatments per week for 3
weeks. Mice were sacrificed 24 hours after the last treat-
ment. Pulmonary function was assayed with a flexiVent
apparatus as described elsewhere.20 Briefly, mice were
anesthetized with pentobarbital, underwent tracheotomy
and cannula placement, and were coupled to the flex-
iVent ventilator apparatus (SCIREQ, Montreal, QC). Mice
were ventilated with a 0.2 mL tidal volume and positive
end-expiratory pressure of 3 cm of H2O. Pressure and
volume were measured and were fit by multiple linear
regression to a linear model of the lung. Methacholine
was delivered via a nebulizer; after each dose, the re-
sponse was measured by applying 2-second perturba-
tions at 10-second intervals for a total of 3 minutes. Dose
response curves were then determined for each of three
parameters that measured lung function.
Serum and BALF Preparation and Studies
After pulmonary function testing, the mice were exsan-
guinated, and sera were prepared with the use of serum
separator tubes (Becton Dickinson, Franklin Lakes, NJ).
Saline (0.8 mL) was instilled in the lungs via the trachea
and withdrawn. BALF cell counts were obtained, and
cytospin slides were prepared for differential cell count-
ing. Slides were stained with Diff-Quik (Siemens, Wash-
ington, DC) and air dried, and Permount coverslips
(Fisher, Pittsburgh, PA) were placed on the slides. The
relative percentages of monocytes, eosinophils, neutro-
phils, and lymphocytes were determined by counting five
high-power fields. After centrifugation, BALF supernatant
fluid and sera were frozen at 80°C for future studies.
qRT-PCR
RNA was prepared from whole lung with the use of an
RNeasy Mini Kit (Qiagen, Valencia, CA), per the manu-
facturer’s instructions. Reverse transcription was per-
formed with Moloney murine leukemia virus reverse trans-
criptase (Applied Biosystems, Foster City, CA) in a
Techne thermal cycler (Bibby Scientific US, Burlington,
NJ). Quantitative RT-PCR (qRT-PCR) was performed with
universal PCR buffer and TaqMan primer/probe assay
reagent (Applied Biosystems) with primers for RAGE
(Mm00545815 m1), IL-5 (Mm00439646 m1), IL-13
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dehydrogenase (GAPDH) control (Mm99999915 g1). The
following sequence was performed on an ABI Prism 7300
machine (Applied Biosystems): 50°C (2 minutes), 95°C
(10 minutes), and then 40 cycles of 95°C (15 seconds)
followed by 60°C (1 minute). The fold change in RAGE,
IL-5, or IL-13 mRNA expression, compared with GAPDH
mRNA housekeeping control, was determined with the
Ct method.
Immunoblotting
Lung homogenates were prepared by homogenizing and
sonicating mouse lungs in cold CHAPS (3[lsqb[(3-chol-
amidopropyl)dimethylammonio]-propanesulfonic acid)
buffer with protease inhibitors (150 mmol/L NaCl, 50
mmol/L Tris-HCl, 10 mmol/L CHAPS, 100 mol/L 3,4-
dichloroisocoumarin, 10 mol/L E-64, 2 mmol/L ortho-
phenanthroline, pH 7.4), followed by protein extraction
over several hours at 4°C. Total protein content in lung
homogenates was determined with the Bradford method.
Ten micrograms of lung homogenate protein, 65 L of
undiluted BALF, or 65 L of 1:10 diluted (in PBS) serum
samples, were analyzed by SDS-PAGE and immunoblot-
ting as described previously.21 After blocking in 5% milk,
membranes were incubated in 1:5000 primary rabbit anti-
RAGE polyclonal antibody (GenScript, Piscataway, NJ)
followed by 1:5000 secondary horseradish peroxidase
anti-rabbit antibody (Jackson ImmunoResearch, West
Grove, PA). For studies that explored the antigen binding
profile of serum IgG from sensitized and challenged
mice, 100 g of HDM extract was separated by SDS-
PAGE under reducing (50 mmol/L dithiothreitol) and
nonreducing (no dithiothreitol) conditions, then trans-
ferred to membranes and blocked in 5% milk. Mem-
branes were then incubated in 1:20 diluted pooled sera
from sensitized and challenged WT or RAGE KO mice
followed by 1:5000 secondary horseradish peroxidase
anti-mouse IgG antibody (Jackson ImmunoResearch).
Membranes were developed with enhanced chemilumi-
nescent detection (Thermo-Fisher, Waltham, MA). Load-
ing control was performed with Ponceau S staining for
BALF and serum and by stripping and reprobing with an
antibody against -actin (Sigma) on lung homogenate
blots.
Immunofluorescence Microscopy
Paraffin-embedded inflation-fixed lungs were sectioned
at a 5-m thickness, mounted on SuperFrost Plus slides
(Fisher), air dried, melted, deparaffinized with xylenes,
and rehydrated with graded ethanol solutions. Antigen
retrieval was performed in 0.2 N HCl with 1 mg/mL pepsin
(Fisher) at 37°C for 10 minutes. Between each step, three
5-minute washes with PBS or PBS containing Tween-20
(PBST) were performed. Sections were blocked with 2%
bovine serum albumin in PBST, whereas primary and
secondary antibody treatments were performed in 0.5%
bovine serum albumin in PBST. To detect RAGE, 1:500
diluted goat polyclonal antibody in serum raised against
full-length mouse sRAGE (GenScript) was used, followedby 1:500 diluted donkey anti-goat antibody conjugated to
cyanine 3 (Jackson ImmunoResearch). Control preim-
mune serum from the same animal in which the RAGE
antibody was raised and additionally RAGE KO lung sec-
tions were used to confirm specificity. Nuclei were
stained with a brief application of Hoechst stain (10 mg/
mL). Sections were coverslipped with gelvatol and exam-
ined by an Olympus IX71 inverted microscope (Olympus,
Tokyo, Japan). All images were processed with ImageJ
software version 1.44o (NIH, Bethesda, MD).22 Images
were background subtracted as individual colors, fol-
lowed by color channels being merged. In all cases a
rolling ball radius of 50.0 pixels was used.
H&E and PAS Staining
Lungs were inflation fixed with 10% neutral-buffered for-
malin, paraffin embedded, cut into sections 5 m thick,
stained with H&E or PAS (Research Histology Services,
University of Pittsburgh), and examined by light micros-
copy All images were processed with ImageJ software
version 1.44o. Images were light background subtracted.
In all cases a rolling ball radius of 50.0 pixels was used.
IgG1, IgE, Eotaxin, Eotaxin-2, IL-4, IL-5, IL-17,
and IL-13 ELISA
Eotaxin, eotaxin-2 (both from Abcam, Cambridge, MA),
IL-4, IL-5 (both from BD Biosciences, San Jose, CA),
IL-17 (R&D Systems, Minneapolis, MN), and IL-13 (eBio-
science, San Diego, CA) enzyme-linked immunosorbent
assays (ELISAs) were performed per manufacturer’s in-
structions, using neat or diluted BALF in all cases except
for IL-17 ELISA, which used neat lung homogenate.
HDM-specific IgG1 ELISA was performed by coating ab-
sorbent plates with 2 g/mL HDM extract in coating buf-
fer (100 mmol/L NaHCO3, 30 mmol/L Na2CO3, pH 9.5)
overnight at 4°C. Between each step, washes were per-
formed with PBST. After blocking with 1% bovine serum
albumin, 1:100 diluted serum or neat lung homogenate
(in CHAPS buffer) was applied and incubated at 4°C
overnight with agitation. Detection was performed by
treating with 1:1000 diluted goat anti-mouse IgG1 conju-
gated to horseradish peroxidase (Jackson ImmunoResearch),
and then o-phenylenediamine dihydrochloride (OPD) sub-
strate (Sigma). Plates were read at 450 nm, and data
were recorded as absolute absorbances. Total IgE ELISA
was performed with an OptEIA IgE ELISA kit (BD Biosci-
ences) per the manufacturer’s instructions. Serum sam-
ples were diluted 1:20 in assay diluent. For HDM-specific
ELISA, HDM extract was first biotinylated with the use of
6-((biotinoyl)amino)hexanoic acid, sulfosuccinimidyl es-
ter (biotin-X, SSE) (Invitrogen, Carlsbad, CA). Then, free
biotin was removed with a Sephadex G-25 quick spin
column (Roche, Indianapolis, IN). Plates were incubated
overnight at 4°C with capture antibody (OptEIA IgE ELISA
kit), then application of 1:5 diluted (in assay diluent) se-
rum overnight at 4°C with agitation. Biotinylated HDM
extract was applied to detect HDM-specific IgE. This was
followed by streptavidin conjugated to horseradish per-
d vascul
cence st
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The plates were read at 450 nm, and data were recorded
as absolute absorbances.
Histologic Scoring
H&E-stained lung sections from C57BL/6 mice were ex-
amined by a board-certified pathologist (T.D.O.) who had
been blinded to the identity of the samples. The total
number of bronchovascular bundles in each lung section
was counted, and inflammation was scored. Inflammation
(if any) in each bronchovascular bundle was graded as 0
(none), 1 (mild), 2 (moderate), or 3 (severe). The results
are expressed as the percentage of all bronchovascular
bundles that involve any inflammatory infiltrates, and, in
addition, as an average severity score obtainable by
dividing the pan-section sum of the bronchovascular
bundle inflammation scores by the total number of bron-
chovascular bundles in that section.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism
Figure 1. Pulmonary RAGE expression and localization is not altered in AA
HDM extract or saline control (mean  SEM of the fold change in RAGE sig
control) in whole lung homogenates of mice treated with HDM extract or sali
for each RAGE isoform, with saline-treated controls set arbitrarily to 1.0 (me
samples of mice treated with HDM extract or saline control. Ponceau S stain se
of mice treated with HDM extract or saline control. Cells and bronchial an
alveolar basement membrane was identified by collagen IV immunofluoresversion 5.0 (GraphPad Software Inc., San Diego, CA),and quantitative results were expressed as means 
SEMs. Statistical significance was determined with two-
way analysis of variance and, when appropriate, un-
paired Student’s t-test. A P value  0.05 was considered
to be significant.
Results
To investigate whether RAGE expression was altered in
mice sensitized and challenged with HDM extract com-
pared with vehicle-treated controls, qRT-PCR and immu-
noblotting on whole lung homogenates were performed.
Although there was a modest decrease in RAGE tran-
script expression in the lungs of mice treated with HDM
extract compared with saline-treated controls (Figure
1A), this difference was not statistically significant. No
change was observed in the overall expression level of
RAGE protein or in the relative proportions of sRAGE
versus two different isoforms of membrane-bound RAGE,
xRAGE,23 and mRAGE (Figure 1B). Finally, sRAGE could
not be detected in BALF or serum of either sensitized/
challenged or naive mice (Figure 1C).
Because RAGE is abundantly expressed by type I
a in mice. A: qRT-PCR of whole lung homogenates of mice treated i.n. with
alized to the GAPDH signal). B: Immunoblot of RAGE and -actin (loading
ol (top panel). Summary of normalized RAGE-to-actin signal intensity ratios
M) (bottom panel). C: Immunoblot probing for RAGE in BALF and serum
loading control.D: RAGE immunofluorescence staining (red) in lung sections
ar structure were identified by nuclear staining (blue), whereas underlying
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closely associated with asthma/AAD, such as bronchial
epithelial cells or inflammatory cells, might be undetectable
by whole lung expression assays. Immunofluorescence mi-
croscopy studies of lung sections performed to address this
question showed no appreciable change in bronchial or
vascular RAGE expression in response to HDM extract sen-
sitization and challenge, and expression in type I alveolar
epithelial cells appeared unaltered (Figure 1D).
Expression of a pathogenetic mediator need not be
altered in a disease state, particularly when the mediator
is a receptor with multiple, potentially mutually antagonis-
tic, roles. Therefore, to explore whether the absence of
RAGE dampens or augments asthma/AAD, RAGE KO
mice on the C57BL/6 background were subjected to the
HDM extract sensitization/challenge protocol, alongside
WT mice for comparison. Pulmonary function testing
showed significant alterations in airway function in WT
mice treated with HDM extract, consistent with an asth-
matic profile (Figure 2A). These changes in responsive-
Figure 2. Mice lacking RAGE do not develop airway hyperresponsiveness,
In all cases results are expressed as means  SEMs (n  6 to 10 per str
methacholine challenge: Rn (Newtonian resistance), G (tissue damping), an
RAGE KO mice treated with HDM extract (top panel). Scale bar  6 m. Su
HDM extract or saline control (bottom panels). C and D: Representative H&
mice treated with HDM extract or saline control. Scale bar  30 m.ness to methacholine challenge were evident in the pa-rameters corresponding to large airway resistance (Rn),
small airway tissue damping (G), and tissue elastance
(H), respectively. The modest change in Rn, compared
with what is often seen in studies in BALB/c mice, was
consistent with findings of previous studies in the
C57BL/6 strain.24 The picture with the Rn parameter was
somewhat complex, with a slightly elevated responsiveness
to methacholine in naive RAGE KOmice compared with WT
counterparts, but no difference between saline- versus
HDM extract-treated RAGE KO mice was seen. Because
there were no observable differences in airway or paren-
chymal architecture in RAGE KO mice, it is likely that any
intrinsic changes in methacholine responsiveness in this
strain are due to a minor effect of RAGE (directly or by
compensatory gene expression) on airway smooth muscle
function (see Discussion for the potential role of IL-17).
However, it is important to note that RAGE KO mice treated
with HDM extract showed G and H parameters indistin-
guishable from those of naive WT and RAGE KO mice.
Modified Romanowsky staining of BALF cells showed
hilia, or increased mucin production in response to HDM extract treatment.
tment group; *P  0.05 versus comparison). A: Airway responsiveness to
ue elastance). B: Representative Romanowsky stain of BALF cells of WT or
f cell counts and differentials in BALF of WT or RAGE KO mice treated with
(C) or PAS stain (D) (red shows mucin) of lung sections of WT or RAGE KOeosinop
ain/trea
d H (tiss
mmary omarkedly elevated cell counts and eosinophilia in the
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Histologic evaluation of lung sections indicated peribron-
chial, perivascular, and interstitial eosinophilia in lungs of
allergic WT mice by H&E staining (Figure 2C), whereas
PAS staining showed goblet cell hyperplasia and ele-
vated expression of mucin in numerous bronchi of the
allergic WT mice compared with controls (Figure 2D). In
contrast to WT mice, RAGE KO mice had essentially no
inflammatory infiltrates and no elevated mucin expression
or goblet cell hyperplasia. These results suggested that
RAGE plays a vital role in the key tissue changes ob-
served in asthma/AAD, including airway hyperrespon-
siveness, eosinophilic peribronchial infiltrates, mucus hy-
persecretion, and airway remodeling.
To determine whether the humoral immune response
to HDM extract sensitization and challenge was altered in
RAGE KO mice, ELISA was performed on sera and lung
homogenates of WT and RAGE KO mice to evaluate the
levels of HDM-specific and total immunoglobulins. Inter-
estingly, significantly elevated levels of HDM-specific
IgG1 in serum and lung homogenate of both WT and
RAGE KO mice that had been sensitized and challenged
with HDM extract were observed (Figure 3A). To testwhether there were broad differences between the HDM
antigen binding profiles of serum IgG from allergen-
primed and -challenged WT versus RAGE KOmice, HDM
extracts separated by SDS-PAGE and transferred to
membranes were probed with sera from sensitized and
challenged WT and RAGE KO mice (Figure 3B), indicat-
ing no differences in antigen binding profiles between the
two strains. Furthermore, the levels of both HDM-specific
IgE and total IgE were significantly elevated in the sera of
both WT and RAGE KO mice sensitized and challenged
with HDM extract, compared with their naive counterparts
(Figure 3C). IL-4 is a key T lymphocyte cytokine involved
in driving CD4 T helper cell differentiation into T helper
type 2 (Th2) cells, as well as in directing B-cell isotype
class switching to IgE synthesis.25 To assess how the ab-
sence of RAGE affected the production of this cytokine in
response to HDM extract sensitization and challenge,
ELISA was performed on BALF samples. The IL-4 re-
sponse was found to be intact in RAGE KOmice, as there
was no significant difference between RAGE KO and WT
mice in the expression of this cytokine in response to
allergen (Figure 3D). Although not a classic cytokine of
Figure 3. Lack of RAGE does not alter the
immunoglobulin response to HDM or affect
the synthesis and secretion of the Th2 cy-
tokine IL-4. In all cases results are ex-
pressed as means  SEMs (n  3 to 10 per
strain/treatment group; *P  0.05 versus
comparison). A: ELISA results show levels
of HDM antigen-specific IgG1 antibodies in
sera and lung homogenates of WT or RAGE
KO mice treated with HDM extract or saline
control. B: Immunoblot shows HDM anti-
gen binding by serum IgG from WT or
RAGE KO mice treated with HDM extract.
C: ELISA results show levels of total IgE or
HDM antigen-specific IgE antibodies in
sera of WT or RAGE KO mice treated with
HDM extract or saline control. D: ELISA
results show levels of IL-4 in BALF of WT or
RAGE KOmice treated with HDM extract or
saline control. E: ELISA results show levels
of IL-17 in lung homogenate of WT or
RAGE KOmice treated with HDM extract or
saline control. DTT, dithiothreitol.the Th2 immune response, IL-17 has been suggested to
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to subtypes with a prominent neutrophilic compo-
nent.26,27 Interestingly, IL-17 appeared to have signifi-
cantly heightened baseline expression in RAGE KO mice
compared with WT mice. However, although the WT mice
showed induction of IL-17 expression in response to
HDM extract sensitization and challenge, the RAGE KO
mice did not (Figure 3E).
In asthma/AAD, eosinophils are thought to contribute to
airway hyperresponsiveness28 and airway remodeling ob-
served in the disease.29 Eotaxins are the main class of
chemokines involved in the selective recruitment of eosino-
phils to the tissues. Thus, to determine whether RAGE me-
diates its effects in the HDM mouse model of asthma/AAD
by inducing eotaxin and/or eotaxin-2 secretion, ELISA was
performed on BALF of WT and RAGE KO mice sensitized/
challenged with HDM extract or with saline control. The
levels of neither eotaxin (Figure 4A) nor eotaxin-2 (Figure
4B) in RAGE KO mice treated with HDM extract were sig-
nificantly changed from baseline, whereas WT mice thus
treated exhibited elevated levels of both chemokines.
IL-5 is a key Th2 cytokine involved in eosinophil prolif-
eration, maturation, survival, function, and recruitment to
tissue.30,31 IL-13, another key Th2 cytokine, acts in a
complementary fashion to IL-5 in that it stimulates
changes in tissue structure and physiology, such as air-
way hyperresponsiveness to methacholine challenge,
goblet cell hyperplasia, and mucus hypersecretion.32 In
addition, IL-13 plays a key role in inducing expression of
the eotaxins.33–36 ELISA on BALF and qRT-PCR on whole
Figure 4. Lack of RAGE abrogates eosinophil-recruiting chemokines eotaxin
and eotaxin-2 as well as Th2 cytokines IL-5 and IL-13. In all cases, results are
expressed as means  SEMs (n  3 to 10 per strain/treatment group; *P 
0.05 versus comparison). A and B: ELISA results show levels of eotaxin (A)
and eotaxin-2 (B) in BALF of WT or RAGE KO mice treated with HDM extract
or saline control. C and D: ELISA results (top panels) show levels of IL-5 (C)
and IL-13 (D) protein in BALF, whereas qRT-PCR results (bottom panels)
show levels of IL-5 (C) and IL-13 (D) transcript in whole lung homogenate of
WT or RAGE KO mice treated with HDM extract or saline control.lung mRNA were performed to assess whether these twokey cytokines are dysregulated in RAGE KO mice receiv-
ing HDM extract. Although expression of IL-5 (Figure 4C)
and IL-13 (Figure 4D) protein and mRNA were signifi-
cantly elevated in WT mice sensitized and challenged
with allergen, these cytokines were not elevated in aller-
gen-challenged RAGE KO mice.
Numerous studies of RAGE in animal models of inflam-
matory disease have suggested that sRAGE has an anti-
inflammatory and generally salutary effect, likely by virtue
of its sequestration of RAGE ligands away from the pro-
inflammatory membrane isoform.37–39 To determine
which of the two isoforms, mRAGE or sRAGE, was driving
the allergic process in the HDM mouse model, and to
explore whether sRAGE has a therapeutic effect (as has
been seen in many other disease models) in WT C57BL/6
mice sensitized and challenged with HDM extract,
sRAGE purified from mouse lungs (Figure 5A) was i.n.
coadministered alongside HDM extract. In addition, to
rule out a nonspecific protein effect, an equal mass of
MSA was coadministered with HDM extract in a separate
group of mice. Asthma/AAD as reflected by total BALF
cell and BALF eosinophil counts was markedly reduced
in mice that had received sRAGE alongside HDM extract
compared with mice that had received either HDM ex-
tract alone or MSA alongside HDM extract (Figure 5B).
H&E-stained lung sections (Figure 5C) were scored by a
pathologist blinded to treatment group for the total num-
ber of bronchovascular bundles, the number of bundles
showing inflammatory infiltrates, and a scoring of the
severity of the inflammation in each bundle. The percent-
age of bronchovascular bundles involving inflammation
and the overall average inflammation severity score were
both significantly reduced in mice given sRAGE along-
side HDM extract compared with the two other HDM
extract sensitized/challenged groups, mirroring the BALF
cell count data (Figure 5D).
A key question of these studies was to what degree, if
any, the role of RAGE in murine models of asthma/AAD
depended on the identity of the epitopes driving the
immune response. An ovalbumin model of asthma/AAD
was used to address this question, because the antigen
profile and sensitization mechanism differ markedly from
that of the HDM model. Sensitization was effected with
the use of aluminum hydroxide-adsorbed ovalbumin ad-
ministered to the peritoneal compartment. Challenge pro-
ceeded i.n., as in the HDM model. Pulmonary function
testing indicated alterations in the Rn, G, and H param-
eters in WT mice treated with ovalbumin compared with
mice treated with saline, analogous to findings in the
HDM model (Figure 6A). Although the change in the Rn
parameter did not reach statistical significance, the
changes in the G and H parameters reached statistical
significance. BALF cell counts were elevated in allergic
WT mice, and eosinophilia was notable (Figure 6B); peri-
bronchial, perivascular, and interstitial eosinophilic in-
flammation (Figure 6C) and mucin overexpression (Fig-
ure 6D) were evident in allergic WT mice compared with
controls. RAGE KO mice have unaltered airway function
and no or minimal BALF eosinophilia, inflammatory infil-
trates, or mucus hypersecretion. These data suggested
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AJP October 2012, Vol. 181, No. 4that RAGE’s role in murine asthma/AAD is independent of
the epitopes involved.
Discussion
The results of this study suggest that RAGE is a key
mediator in the disease mechanisms that eventuate in
airway hyperresponsiveness, mucus hypersecretion and
airway remodeling, and pulmonary eosinophilia in an
HDM mouse model of asthma/AAD. Taking into consid-
eration the great difference in response of the WT versus
RAGE KO mice to HDM extract sensitization/challenge, it
is perhaps surprising that RAGE levels and localization in
the pulmonary compartment appear to be essentially un-
changed between allergen- and vehicle control-treated
groups. This might invite the suggestion that it is not
RAGE itself, but rather a protein whose expression is
tightly linked to RAGE, that is responsible for the effects
seen in RAGE KO mice. Although this possibility cannot
be definitively excluded, given the observation that treat-
ment with sRAGE (a decoy for RAGE ligands) specifically
and markedly reduces bronchovascular inflammation in
response to HDM extract sensitization/challenge sug-
gests that (lack of) RAGE itself, rather than a compensa-
tory process in KO animals, is responsible for the effect
seen. Furthermore, the sRAGE treatment studies indicatethat manipulation of the RAGE signaling axis via admin-
istration of sRAGE, antagonistic antibodies, or small mol-
ecule inhibitors, may have promise in the treatment of
asthma/AAD.
The data suggest that innate and adaptive immune
response mechanisms that drive humoral immunity are
intact in the absence of RAGE, including antigen recog-
nition, processing, and presentation; B-lymphocyte pro-
duction of immunoglobulin; and isotype class switching,
this latter phenomenon being driven by IL-4. Although T
lymphocytes are thought to be the main source of IL-4,
IL-5, and IL-13, other cell types have been linked to the
production of one or more members of this triad. Thus,
IL-4 induction in the absence of the other two canonical
Th2 cytokines could be reflective of either uncoupling in
the cytokine response at the T-cell level or the recruitment
of other cell types that may produce IL-4, such as mac-
rophages40 or basophils.41 The fact that immunoglobulin
production in response to antigens occurs in the absence
of RAGE, despite the lack of other features associated
with AAD, is consistent with prior studies suggesting that
B-cell deficiency (and hence immunoglobulin produc-
tion) does not affect the physiologic and pathologic
changes seen in response to antigen sensitization and
challenge in an ovalbumin mouse model of asthma/
Figure 5. sRAGE treatment decreases HDM-in-
duced pulmonary inflammation. In all cases, results
are expressed as means SEMs (WTHDM, n 3; all
other treatment groups, n  4; *P  0.05 versus
comparison). A: SDS-PAGE separation and Coomas-
sie Brilliant Blue staining of 5 g of MSA or mouse
sRAGE. B: Total cell and eosinophil counts and dif-
ferentials in BALF of WT mice treated with HDM
extract versus saline control, in each case alone or
alongside MSA or sRAGE treatment. C: Represen-
tative H&E stain of lung sections of WT mice
treated with HDM extract or saline control along-
side no additional protein, MSA, or sRAGE. Scale
bar  30 m. D: Bronchovascular bundle inflam-
mation in mice treated with HDM extract or saline,
with or without MSA or sRAGE treatment. Results
are expressed as percentage of airways involved or
average severity across all bronchovascular bun-
dles (0  no inflammatory infiltrate, 1  mild
inflammatory infiltrate, 2moderate inflammatory
infiltrate, and 3  severe inflammatory infiltrate).AAD.42 Furthermore, the fact that in the presence of high
albumin
lbumin
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hypersensitivity, eosinophilia, or remodeling would seem
to indicate that IgE alone is not playing a central mech-
anistic role in this model of asthma, although it must be
noted that changes in airway physiology were assayed
with graded doses of methacholine rather than allergen.
IL-17 has been suggested to play a role in allergy and
asthma; in the HDM model of asthma/AAD, IL-17 is up-
regulated in response to allergen sensitization and chal-
lenge in WT mice.43 That RAGE KO mice showed no
IL-17 induction in response to HDM extract, and further-
more showed heightened baseline expression of IL-17 in
the absence of antigen, suggests that RAGE plays a role
in IL-17 regulation. RAGE may actively inhibit the secre-
tion of IL-17, directly or by disrupting precursor cyto-
kines, such as IL-23. Conversely, the absence of RAGE
may lead to compensatory induction of other factors that
in turn drive the IL-23/IL-17 axis. Although IL-17 has been
shown to play a role in neutrophilic asthma,44 it has also
been shown to be a negative regulator of established
allergic asthma.45,46 The baseline elevation of IL-17 in
Figure 6. Mice lacking RAGE do not develop airway hyperresponsiveness
Results are expressed as means  SEMs (n  8 to 10 per strain/treatment
challenge, as indicated by the Rn, G, and H parameters. B: Representative BA
bar  6 m. Summary of BALF data of WT or RAGE KO mice treated with ov
or PAS stain (D) of lung sections of WT or RAGE KO mice treated with ovaRAGE KO mice may thus impede the initiation of a pri-mary asthmatic response. Moreover, it may account for
the subtle differences in airway responsiveness to meth-
acholine challenge between naive saline-treated WT and
RAGE KO mice (RAGE KO mice treated with saline
showed an elevated Rn parameter compared with WT
mice thus treated), as a number of studies have indicated
a role for IL-17 in promoting airway hyperresponsive-
ness.47–50 As an asthmatic response is not initiated in the
RAGE KO mice treated with HDM extract (as evidenced
by pulmonary function parameters, histology, and cytokine
profiling), it is not particularly surprising that in this strain
there was no consequent up-regulation in IL-17 from base-
line in response to allergen.
The cytokine and chemokine data presented herein
show that canonical molecular mediators of eosinophil
recruitment and airway remodeling, such as IL-5 and
IL-13, are indeed abrogated in the absence of RAGE,
suggesting that RAGE likely acts as a proximal mediator
in one or more proinflammatory pathways that eventuate
in the altered physiology and histology seen in this model
of asthma/AAD. Because of its multivalency, RAGE has
philia, or increased mucin production in response to ovalbumin treatment.
*P  0.05 versus comparison). A: Airway responsiveness to methacholine
of WT or RAGE KO mice treated with ovalbumin extract (top panel). Scale
or saline control (bottom panels). C and D: Representative H&E stain (C),
or saline control. Scale bar  30 m., eosino
group;
LF cellsfor some time been considered by many to be a patho-
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nous ligand has been discovered. Studies in the ovalbu-
min model of asthma suggest that RAGE KO mice are
resistant to the tissue and physiological changes seen in
WT mice treated with antigen, notably hypersensitivity to
methacholine challenge, pulmonary eosinophilic inflam-
mation, and airway remodeling. Given the substantial
differences in the sensitization process and the disparate
immune epitopes involved between the HDM and ovalbu-
min models, and taking into consideration the integrity of
the immunoglobulin response against HDM antigens in
RAGE KO mice, it is reasonable to conclude that RAGE
acts downstream of antigen recognition; thus, its ligands
in asthma/AAD are likely to be endogenous and not de-
rived from the initial antigenic stimulus. Finally, although
RAGE is predominantly expressed on alveolar type I ep-
ithelial cells, some studies have suggested that it is ex-
pressed on hematopoietic cells and endothelium as well.
Characterization of the cell type(s) responsible for the
effect seen in these studies (not necessarily those with
the greatest expression), as well as elucidation of the
molecular pathways between RAGE and the T-cell cyto-
kines IL-5 and IL-13, will constitute key aims of future
studies.
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